Recommended therapy for patients with pulmonary arterial hypertension is generally a combination of an endothelin receptor antagonist and a phosphodiesterase type 5 inhibitor. In this touchCARDIO interview, we speak with Dr Kelly Chin (UT Southwestern Medical Centre, Dallas, TX, USA) to discuss the treatment paradigm.
Dr Chin presented an abstract entitled ‘Efficacy And Safety Of Macitentan Tadalafil Fixed Dose Combination In Pulmonary Arterial Hypertension: Results From The Randomized Controlled Phase III A DUE Study’ (Abstract number 409-14) at ACC.23 Together With WCC (ACC.23/WCC) in New Orleans, 4–6 March 2023.Â
Click here to view the video on the A DUE trial.
Question:
Could you give us a brief overview of the treatment paradigm for patients with pulmonary arterial hypertension? (0:16)
Disclosures: Kelly Chin is a consultant for Acceleron, Gossamer Bio, Janssen, Merck and United Therapeutics, and has received grant/research support from Acceleron, Altavant, Gossamer Bio, Janssen, Merck and United Therapeutics.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.
Filmed as a highlight of ACC 2023
Access more content on hypertension here
Transcript:Â
Hi, I’m Kelly Chin from UT Southwestern in Dallas, Texas. And I’m the Director of our pulmonary hypertension program here.Â
Q. Could you give us a brief overview of the treatment paradigm for patients with pulmonary arterial hypertension?
The standard of care for pulmonary arterial hypertension currently is outlined in treatment guidelines. For most patients, the recommended initial therapy is treatment with a combination of an endothelin receptor antagonist and a phosphodiesterase type 5 inhibitor. There are some exceptions to this recommendation. Patients who are very sick should generally be also started on an intravenous or subcutaneous prostacyclin. Some patients, who are at higher risk of complications, should be started on one medication at a time.Â
Subtitles and transcript are autogenerated
